These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 8077509)

  • 1. Antifungal therapy of yeast infections.
    Hay RJ
    J Am Acad Dermatol; 1994 Sep; 31(3 Pt 2):S6-9. PubMed ID: 8077509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the treatment of superficial candida infections.
    Goldstein SM
    Semin Dermatol; 1993 Dec; 12(4):315-30. PubMed ID: 8312148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onychomycosis. Agents of choice.
    Hay RJ
    Dermatol Clin; 1993 Jan; 11(1):161-9. PubMed ID: 8382121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.
    Tumbarello M; Caldarola G; Tacconelli E; Morace G; Posteraro B; Cauda R; Ortona L
    J Antimicrob Chemother; 1996 Oct; 38(4):691-9. PubMed ID: 8937963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Itraconazole in the treatment of superficial cutaneous and mucosal Candida infections.
    Del Rosso JQ; Zellis S; Gupta AK
    J Am Osteopath Assoc; 1998 Sep; 98(9):497-502. PubMed ID: 9785744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review.
    Evans EG
    J Am Acad Dermatol; 1998 May; 38(5 Pt 3):S32-36. PubMed ID: 9594934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onychodystrophy as the only sign of congenital candidiasis.
    Joy Way Bueno SM; Santos Muñoz A; Maldonado I; Larralde M
    Pediatr Dermatol; 2020 Jan; 37(1):159-161. PubMed ID: 31630427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
    Gupta AK
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candida onychomycosis--an evaluation of the role of Candida species in nail disease.
    Hay RJ; Baran R; Moore MK; Wilkinson JD
    Br J Dermatol; 1988 Jan; 118(1):47-58. PubMed ID: 3342176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral candidosis--clinical challenges of a biofilm disease.
    Rautemaa R; Ramage G
    Crit Rev Microbiol; 2011 Nov; 37(4):328-36. PubMed ID: 21777047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection.
    Vazquez JA
    Pharmacotherapy; 1999 Jan; 19(1):76-87. PubMed ID: 9917080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of nondermatophyte mold and Candida onychomycosis.
    Tosti A; Piraccini BM; Lorenzi S; Iorizzo M
    Dermatol Clin; 2003 Jul; 21(3):491-7, vii. PubMed ID: 12956201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onychomycosis: Diagnosis and management.
    Singal A; Khanna D
    Indian J Dermatol Venereol Leprol; 2011; 77(6):659-72. PubMed ID: 22016272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous candidosis in immunosuppressed patients.
    Jautová J; Baloghová J; Dorko E; Pilipcinec E; Svický E; Danko J; Tkáciková L
    Folia Microbiol (Praha); 2001; 46(4):359-60. PubMed ID: 11830950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Candida mycoses].
    Grimmer H
    Z Haut Geschlechtskr; 1968 Nov; 43(22):943-8. PubMed ID: 5714942
    [No Abstract]   [Full Text] [Related]  

  • 16. [Onychomycosis-causing yeasts in four Mexican dermatology centers and their antifungal susceptibility to azolic compounds].
    Manzano-Gayosso P; Méndez-Tovar LJ; Arenas R; Hernández-Hernández F; Millán-Chiu B; Torres-Rodríguez JM; Cortés-González E; Fernández R; López-Martínez R
    Rev Iberoam Micol; 2011; 28(1):32-5. PubMed ID: 21147249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of oropharyngeal candidiasis in HIV-positive patients.
    Greenspan D
    J Am Acad Dermatol; 1994 Sep; 31(3 Pt 2):S51-5. PubMed ID: 7915732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.
    Gupta AK; Shear NH
    Drug Saf; 2000 Jan; 22(1):33-52. PubMed ID: 10647975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients.
    Vazquez JA
    HIV Clin Trials; 2000; 1(1):47-59. PubMed ID: 11590489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onychomycosis: a proposed revision of the clinical classification.
    Hay RJ; Baran R
    J Am Acad Dermatol; 2011 Dec; 65(6):1219-27. PubMed ID: 21501889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.